ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Inflammation"

  • Abstract Number: 0931 • ACR Convergence 2025

    Reduced mitophagy in salivary glands of Sjögren’s disease patients is associated with mitochondrial structural damage

    Salvador Campos1, Sergio Aguilera2, Juan Gutiérrez1, Isabel Castro3, Patricia Carvajal3, Lorena Carvajal1, Sergio González4, Claudio Molina5, María-Julieta González6 and María-José Barrera5, 1Universidad San Sebastián, Santiago, Region Metropolitana, Chile, 2Clinica Indisa, Santiago, Region Metropolitana, Chile, 3Departamento de Tecnología Médica, Facultad de Medicina, Universidad de Chile, Santiago, Region Metropolitana, Chile, 4Escuela de Odontología, Universidad Mayor, Santiago, Region Metropolitana, Chile, 5Facultad de Odontología, Universidad San Sebastián, Santiago, Region Metropolitana, Chile, 6ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Region Metropolitana, Chile

    Background/Purpose: Primary Sjögren's disease (pSjD) is a systemic autoimmune disease characterized mainly by immune-mediated damage to exocrine glands. Previously, we found decreased expression of ATG5…
  • Abstract Number: 0836 • ACR Convergence 2025

    Growth Differentiation Factor-15 Predicts Frailty and Death in Rheumatoid Arthritis

    Katherine Wysham1, Hannah Brubeck2, Aaron Baraff2, Christian Lood3, Punyasha Roul4, Bryant England5, Beth Wallace6, Grant Cannon7, Gary Kunkel8, Ted Mikuls5, Patti Katz9, Dolores Shoback10, Jose Garcia11, Ariela Orkaby12, Joshua Baker13 and Tate Johnson5, 1VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 2VA Puget Sound Health Care System, Seattle, WA, 3University of Washington, Seattle, WA, 4UNMC, Omaha, NE, 5University of Nebraska Medical Center, Omaha, NE, 6Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 7University of Utah and Salt Lake City VA, Salt Lake City, UT, 8University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 9UCSF, San Rafael, CA, 10San Francisco VA Medical Center & University of California San Francisco, San Francisco, CA, 11VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, 12VA Boston Healthcare System & Division of Aging, Brigham and Women’s Hospital, Harvard Medical School & VA Geriatrics Research Education and Clinical Center, Boston, MA, 13University of Pennsylvania, Philadelphia, PA

    Background/Purpose: RA is associated with premature aging and frailty. Growth differentiation factor-15 (GDF-15) is a biomarker that increases in response to cellular stress and inflammation…
  • Abstract Number: 0277 • ACR Convergence 2025

    A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Ascending Doses and Food Effects of BGB-45035, a chimeric degradation activating compound (CDAC), in Healthy Participants

    Vaibhav Mundra1, Cunjing Yu2, Roland Morley1, Yuan Yuan3, Yifan Qin3, Jingjing Schneider1, Shengnan Chen3, Zhenyuan Zhou3 and Zhen Yao2, 1BeOne Medicines USA, Inc., San Carlos, CA, 2BeOne Medicines (Beijing) Co, Ltd., Beijing, China (People's Republic), 3BeOne Medicines (Shanghai) Co, Ltd., Shanghai, China (People's Republic)

    Background/Purpose: Interleukin 1 receptor associated kinase 4 (IRAK4) degradation may modulate toll-like receptor signaling and alleviate symptoms in rheumatoid arthritis and atopic dermatitis.1,2 BGB-45035, an…
  • Abstract Number: 0080 • ACR Convergence 2025

    The Role of DICAM in Modulating Macrophage Differentiation and Inflammatory Responses via αvβ3 Integrin Signaling in Rheumatoid Arthritis

    Hanna Lee1, Youn-Kwan Jung2, Sang-il Lee3, Yun-Hong Cheon4 and Hyunjin Lim4, 1Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University Hospital, Changwon, Changwon-si, Kyongsang-namdo, Republic of Korea, 2Institute of Medical Science, Gyeongsang National University, Jinju, Jinju, Kyongsang-namdo, Republic of Korea, 3Department of Internal Medicine and Institute of Medical Science, College of Medicine, Gyeongsang National University and Hospital, Jinju, Republic of Korea, 4Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Jinju, Kyongsang-namdo, Republic of Korea

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent joint inflammation, cartilage destruction, and bone erosion. Among the various immune cells involved…
  • Abstract Number: 0074 • ACR Convergence 2024

    Tofacitinib Therapy Ameliorates Inflammation in a Mouse Model of Psoriasis and Arthritis by Inducing Type 2 Immunity

    Maria de la Luz Garcia-Hernandez1, Javier Rangel-Moreno1, Ananta Paine2, Angel Rangel-Garcia1, Marissa Krantz3, Delaney Martino1, Marc Nuzzo1 and Christopher Ritchlin4, 1University of Rochester, Rochester, NY, 2ORNA Tx, Southborough, MA, 3University of Rochester, Rochester, NY, 4Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY

    Background/Purpose: Psoriatic arthritis (PsA), a chronic progressive inflammatory arthritis, affects peripheral joints and causes patient disability. PsA patients also have skin plaques initiated by activation…
  • Abstract Number: 0465 • ACR Convergence 2024

    Therapeutic Drug Monitoring of the Adalimumab Biosimilar (AMJEVITA™, Adalimumab-atto) Using Originator Adalimumab and Anti-Adalimumab Antibody Assays

    Monique Bastidas1, Lythou Yeo1, Susie Magpantay1, Judah Scott1, Mike Zikry1, Wayne Galdamez1, Jane Yang2 and Kelly Chun1, 1Labcorp, Calabasas, CA, 2LabCorp, Weston, MA

    Background/Purpose: Treatment of RA with biologic TNF inhibitors is effective in reducing disease activity and improving radiographic progression outcomes. Therapeutic drug monitoring (TDM) of adalimumab…
  • Abstract Number: 0813 • ACR Convergence 2024

    Investigating TASL, SLC15A4, & TLR7 Associated Risk SNPs in Systemic Lupus Erythematosus

    Christina G. Bruxvoort1, Faith A. Porter1, Joshua W. Cavett1, John A. Ice2, Batool Bilal1, R Hal Scofield1 and Valerie M. Lewis1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2OKC Veteran's Affairs Medical Center, Oklahoma City

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease that mostlyhas it onset among women between the ages 15–44. While the global pathogenic…
  • Abstract Number: 0936 • ACR Convergence 2024

    Schnurri-3 Inhibition Protects from NF-kB-induced Bone Loss in Inflammatory Arthritis

    Priyanka Kushwaha1, Catherine Manning2, Tadatoshi Sato3, Yeon-Suk Yang3, Jae-Hyuck Shim4 and Ellen Gravallese5, 1Department of Medicine/Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, 2Brigham and Women's Hospital, Dedham, MA, 3Department of Medicine/Division of Rheumatology, Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, 4University of Massachusetts, Worcester, MA, 5Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: In rheumatoid arthritis (RA), production of TNF promotes osteoclast activity and inhibits osteoblasts (OBs) and bone healing. Schnurri-3 (SHN3) is a potent suppressor of…
  • Abstract Number: 1473 • ACR Convergence 2024

    Patient-Reported Symptoms Improved with Stringent Control of Swollen Joints in Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab

    M. Elaine Husni1, Philip Mease2, Dafna Gladman3, Barbara Ink4, Jérémy Lambert5, Patrick Healy6 and Laure Gossec7, 1Cleveland Clinic, Cleveland, OH, 2Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4UCB Pharma, Slough, United Kingdom, 5UCB Pharma, Colombes, France, 6UCB Pharma, Morrisville, NC, 7Sorbonne Université, Paris, France

    Background/Purpose: PsA is characterized by joint and skin inflammation, and associated with debilitating symptoms of pain and fatigue.1 Previous research has shown that pain and…
  • Abstract Number: 1794 • ACR Convergence 2024

    Biobehavioral Basis and Outcomes of Cognitive Dysfunction in Childhood Systemic Lupus Erythematosus

    Hanne van der Heijden1, Andrea Knight2, Itamar Ronen3, Gabrielle Alonzi4, Kyle McBrearty4, Aditi Deokar4, Joseph Gonzalez-Heydrich4, Joyce Chang4 and Jaymin Upadhyay5, 1Boston Children's Hospital Harvard Medical School, Boston, MA, 2Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 3Brighton and Sussex Medical School, University of Sussex, Brighton, UK, Brighton, United Kingdom, 4Boston Children's Hospital, Boston, MA, 5Boston Children's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Cognitive dysfunction (CD) in childhood-onset SLE (cSLE) is undertreated yet profoundly impacts lifelong health-related quality of life. Investigating CD in cSLE is crucial, given…
  • Abstract Number: 2002 • ACR Convergence 2024

    Pain and Physical Function, but Not Fatigue, Track with Disease Activity in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis

    Laura Cappelli1, Cyd Eaton1, Yunzhi Wang1, Michelle Jones2 and Clifton Bingham3, 1Johns Hopkins School of Medicine, Baltimore, MD, 2Johns Hopkins School of Medicine, Pittsburgh, PA, 3Johns Hopkins University, Baltimore, MD

    Background/Purpose: Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an impactful and often persistent side effect of cancer immunotherapy that can lead to permanent joint damage…
  • Abstract Number: 2511 • ACR Convergence 2024

    Clinical Characteristics and Outcomes of Patients with Clinically Isolated Aortitis

    Mahmut Kaymakci1, Hannah Langenfeld1, Andrew C. Hanson2, Cynthia Crowson1, Melanie Bois1, Hartzell Schaff2, Mohanad Elfishawi3, Matthew Koster1, Cornelia Weyand2 and Kenneth Warrington1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, 3University of Minnesota, Minneapolis

    Background/Purpose: Clinically Isolated Aortitis (CIA) is a type of vasculitis affecting the aorta in the absence of systemic vasculitis, rheumatic disease, or infection. Most patients…
  • Abstract Number: 2690 • ACR Convergence 2024

    ANCA IgG Promotion of Neutrophil Recruitment, Migration and Vascular Damage in ANCA Associated Vasculitis May Be Enhanced by Hypoxia

    Noelle Pisacano, Amrita Dhutia, Stephen Rothery, Charles Pusey, Edwin Chilvers, Andrew Cowburn, Katharine Lodge and Maria Prendecki, Imperial College London, London, United Kingdom

    Background/Purpose: Neutrophils are main mediators of disease in ANCA associated vasculitis (AAV). Pathogenic ANCA IgG on neutrophils promotes neutrophil adhesion and migration at the endothelium.…
  • Abstract Number: 0079 • ACR Convergence 2024

    Characterization of the Tissue Resident Memorial T Cells in Autoimmune Arthritis: A Comparative Study of Psoriatic Arthritis and Rheumatoid Arthritis

    Siba Raychaudhuri1, Christine Abria2 and Smriti K Raychaudhuri3, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, 2VA Medical Center Sacramento, Mather, CA, 3VA Sacramento Medical Center, Mather, CA

    Background/Purpose: Tissue-resident memory T cells (TRM) cells can drive localized, recurrent inflammation. TRM are site-specific T cells that take up long-term residence in peripheral tissues…
  • Abstract Number: 0493 • ACR Convergence 2024

    An Algorithm Pipeline for Automated Metrical Analysis of Joint Swelling in Rheumatoid Arthritis via Smartphone Hand Photographs

    Cinja Koller1, Marc Blanchard2, Jules Maglione3, Patrick Hermann4 and Thomas Huegle3, 1Doctoral School, Faculty of Biology and Medicine, University of Lausanne, Genève, Vaud, Switzerland, 2CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, Perroy, Switzerland, 3Lausanne University Hospital, Lausanne, Switzerland, 4Lausanne University Hospital, Lausanne, Vaud, Switzerland

    Background/Purpose: Advancement in technology has fostered Remote Patient Monitoring (RPM), but it is mainly subjectively measured by patient reported outcomes or non-specifically via wearable data.…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 67
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology